<?xml version="1.0" encoding="UTF-8"?>
<p>A benevolent Artificial intelligence (AI)s knowledge graph and customizations bespoke to SARS-CoV-2 were used together to identify drugs that may halt the viral infection process. Baricitinib was expected to have a high binding affinity to AAK1 and cyclin G-associated kinase, another regulator of endocytosis [
 <xref rid="B72-pharmaceuticals-13-00096" ref-type="bibr">72</xref>]. Accordingly, baricitinib is suggested to be trialed on patients with SARS-CoV-2 acute respiratory disease in order to reduce the viral entry and the associated inflammation (NCT04321993).
</p>
